

Eurofins reinforces its leadership in the Benelux Food and Feed testing market with the acquisition of KBBL

28 February 2014

Eurofins Scientific (EUFI.PA), the global leader in food and feed testing, announces the acquisition of KBBL, one of the leading food and water testing service providers in The Netherlands, from Gezondheidsdienst voor Dieren (GD), a leading company in animal health management.

KBBL generates revenues in excess of EUR 7m, and has established a strong reputation in the domestic food and water testing market since its foundation in 1990. It is also a reference laboratory for meat testing. KBBL offers the full spectrum of analytical testing for the food industry and enjoys long-standing relationship with food producers, consultancy firms and other laboratories in the domestic market. As part of the transaction, Eurofins will continue a strategic cooperation with GD providing it with analytical services geared for the food sector.

KBBL is a strategic fit for Eurofins both in operational competence, and geographic location. The acquisition provides Eurofins access to the complex but attractive domestic meat testing market, and allows KBBL to further develop this competence, whilst Eurofins can provide a more optimal platform for other laboratory activities that they currently perform at low volumes. In addition, KBBL's competence in drinking water testing reinforces Eurofins' leadership in this market. Furthermore, KBBL's laboratory is ideally located in Wijhe, between Eurofins' food testing hubs in Heerenveen and Barendrecht, and is in close proximity to the Group's water testing activities in Deventer, for easy access to the various competencies and logistical network of the Group.

For more information, please visit www.eurofins.com or contact:

Eurofins Investor Relations Phone: +32-2-766 1620 E-mail: ir@eurofins.com

Notes for the editor:

Eurofins – a global leader in bio-analysis

Eurofins Scientific is the world leader in food and pharmaceutical products testing. It is also number one in the world in the field of environmental laboratory services and one of the global market leaders in agroscience, genomics, discovery pharmacology and central laboratory services.

With about 15,000 staff in more than 190 laboratories across 36 countries, Eurofins offers a portfolio of over 100,000 reliable analytical methods for evaluating the safety, identity, composition, authenticity, origin and purity of biological substances and products. The Group provides its customers with high-quality services, accurate results in time and expert advice by its highly qualified staff.

Eurofins is committed to pursuing its dynamic growth strategy by expanding both its technology portfolio and its geographic reach. Through R&D and acquisitions, the Group draws on the latest developments in the field of biotechnology and analytical chemistry to offer its clients unique analytical solutions and the most comprehensive range of testing methods.

As one of the most innovative and quality oriented international players in its industry, Eurofins is ideally positioned to support its clients' increasingly stringent quality and safety standards and the expanding demands of regulatory authorities around the world.

The shares of Eurofins Scientific are listed on the NYSE Euronext Paris Stock Exchange (ISIN FR0000038259, Reuters EUFI.PA, Bloomberg ERF FP).

Important disclaimer:

This press release contains forward-looking statements and estimates that involve risks and uncertainties. The forward-looking statements and estimates contained herein represent the judgement of Eurofins Scientific' management as of the date of this release. These forward-looking statements are not guarantees for future performance, and the forward-looking events discussed in this release may not occur. Eurofins Scientific disclaims any intent or obligation to update any of these forward-looking statements and estimates. All statements and estimates are made based on the information available to the Company's management as of the date of publication, but no guarantee can be made as to their validity.